
    
      The primary objective of the study is to collect long-term safety information on anetumab
      ravtansine and to enable patients, who received an anetumab ravtansine-containing treatment
      in any Bayer-sponsored anetumab ravtansine parent study, to continue the treatment. The
      secondary objective is to further investigate the efficacy of the drug.
    
  